ConductScience.org, home

Paper41360893

Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study.

Isfahani MM and 4 others. Sci Rep, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study. Papers, record 41360893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41360893

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of prevalence of fatty liver disease according to the different nomenclatures of NAFLD, MAFLD, and MASLD in a large Iranian Population-based study.
PubMed
Journal
Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article, Comparative Study
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-01-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Isfahani MMMarjan Moallemian
2Sepanlou SGSadaf G
3Joukar FFarahnaz
4Mansour-Ghanaei FFariborz
5Taheri EEhsaneh

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Non-alcoholic Fatty Liver DiseaseMajor topic
Fatty LiverMajor topic
Humans
Male
Iran
Female
Prevalence
Middle Aged
Adult
Cohort Studies
Aged

Source PubMed

Download CSV of topics

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140016310Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021.Sci Rep2025https://conductscience.org/library/papers/40016310PubMed
236626630The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023https://conductscience.org/library/papers/36626630PubMed
336695773Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.Eur J Gastroenterol Hepatol2023https://conductscience.org/library/papers/36695773PubMed
438403071MASLD identifies patients with significant hepatic fibrosis and steatosis in fatty liver population.Ann Hepatol2024https://conductscience.org/library/papers/38403071PubMed
538234088Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.Hepatol Res2024https://conductscience.org/library/papers/38234088PubMed
629145581Prospective Epidemiological Research Studies in Iran (the PERSIAN Cohort Study): Rationale, Objectives, and Design.Am J Epidemiol2018https://conductscience.org/library/papers/29145581PubMed
737453612A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.J Hepatol2024https://conductscience.org/library/papers/37453612PubMed
838317478Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: results from a single-center biopsy study.Chin Med J (Engl)2024https://conductscience.org/library/papers/38317478PubMed
937363821A multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology2023https://conductscience.org/library/papers/37363821PubMed
1038587293High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.Am J Gastroenterol2024https://conductscience.org/library/papers/38587293PubMed
1130821159The PERSIAN Guilan Cohort Study (PGCS).Arch Iran Med2019https://conductscience.org/library/papers/30821159PubMed
1237714381Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD.J Hepatol2024https://conductscience.org/library/papers/37714381PubMed
1319766548Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.Dig Liver Dis2010https://conductscience.org/library/papers/19766548PubMed
1440287355Transitioning from NAFLD to MAFLD to MASLD in the Mexican population.Rev Gastroenterol Mex (Engl Ed)2025https://conductscience.org/library/papers/40287355PubMed
1539564428Comparison of NAFLD, MAFLD, and MASLD Prevalence and Clinical Characteristics in Asia Adults.J Clin Exp Hepatol2025https://conductscience.org/library/papers/39564428PubMed
1637822312The heated debate over NAFLD renaming: An ongoing saga.Hepatol Forum2023https://conductscience.org/library/papers/37822312PubMed
1738076354Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis.J Clin Exp Hepatol2024https://conductscience.org/library/papers/38076354PubMed
1834871813An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.Clin Gastroenterol Hepatol2023https://conductscience.org/library/papers/34871813PubMed
1932278004A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol2020https://conductscience.org/library/papers/32278004PubMed
2035562658Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.BMC Gastroenterol2022https://conductscience.org/library/papers/35562658PubMed

See all 30 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42277871Higher adherence to the EAT-lancet diet is associated with reduced risk of metabolic dysfunction-associated steatotic liver disease: a 5-year middle eastern cohort study.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42277871PubMed
42115302Association of general obesity, metabolically healthy obesity, and abdominal adiposity markers with elevated liver enzymes: a population-based study.Sci Rep2026https://conductscience.org/library/papers/42115302PubMed
42074043The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease.Int J Mol Sci2026https://conductscience.org/library/papers/42074043PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41360893

GET https://conductscience.org/api/papers/v1/41360893/references?page=2